Fundraising FoxLong Game
Venture capitalLondon · Pre-Seed–Seed · 9 people tracked
Find your way into Long Game
Sign up to see every warm intro you have to Long Game
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Long Game team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
LongGame backs longevity biotech companies developing technologies capable of significantly extending healthy human lifespan, with a hard rule that every investment must have the potential to add at least 10+ years of healthy life. The firm targets aging at its root cause, aiming to slow or reverse its effects, and prioritizes solutions that are broadly scalable for global populations rather than only the wealthy. It cites breakthroughs in AI, synthetic biology, stem cell therapies, gene sequencing and editing, protein engineering, and tissue engineering, alongside aging demographics and a trillion-dollar market opportunity, as reasons the sector is poised for growth. Investments must be grounded in credible scientific research and strong ethical foundations.
Source: firm website, verified Oct 10, 2026.
Team · 9 people
from the firm's website & public directories
What they invest in
from 16 of 21 portfolio companiesBiotech ×13Healthtech ×9AI & Machine Learning ×8Deep Tech ×7Longevity ×6Digital Health ×4Medical Devices ×4Wellness & Fitness ×2
HQs:United States×11Switzerland×1France×1
Who they back
founder profiles across 14 portfolio companiesFounding team size:solo founder×72 founders×33 founders×24+ founders×2
Where their founders studiedfrom 19 founders with education data
Case Western Reserve University ×2EPFL ×2Stanford University ×2
What their founders studiedfrom 18 founders with field-of-study data
Life Sciences ×8Engineering ×6Computer Science ×3Physics ×3
Where their founders worked beforefrom 19 founders with career history
iGEM Competition ×2Sana Biotechnology ×2
Accelerator rootsportfolio companies that came through a program
Investments · 21 tracked
founders shown can be your intro pathBy year:2025 · 22019 · 13 dated
Adaptyv Bio develops technologies for protein engineering that enable the design and testing of new proteins for applications in medicine, industrial enzymes, and functional materials.
AI & Machine LearningBiotechDeep TechHealthtechLausanne, CH
Julian Englert(Founder)inDaniel Nakhaee-Zadeh Gutierrez(Founder)inRobert KapturinGerard AntouninSam BurnsinDaniel Nakhaee-Zadeh(CTO)in
Co-investorsFoundersHAWKTAILHighland EuropeNeer Venture PartnersRheingau FoundersS2S Ventures+11 more
Aperture Therapeutics uses machine learning to mine genomic and clinical datasets for naturally occurring protective gene variants, then designs oligonucleotide therapeutics that mimic those variants to treat neurodegenerative diseases such as ALS and FTD and delay brain aging.
AI & Machine LearningBiotechLongevity
Martin Jacko(Founder & CEO)in
Co-investorsage1XEIA Venture Partners
Cirrus Therapeutics is a biotech developing gene and cell therapies based on ocular immunology to treat dry age-related macular degeneration (AMD), including an AAV gene therapy to restore the IRAK-M immune regulator and a next-generation retinal pigment epithelium (RPE) cell therapy for advanced geographic atrophy.
BiotechHealthtechLongevityCambridge, US
Ying Kai Chan(Co-founder & CEO)inAndrew Dick(Director, Promoter)
BoardAlexandra Cantley(Director)inKhoo Shih(Director)
Co-investorsClavystBioZAKA VCPolaris Partners
Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders.
BiotechDigital HealthLongevitySan Francisco, US
Robin Mansukhani(CEO and Co-Founder)inAnil Bhushan(Scientific Founder)in
BoardDylan Morris(Director)in
Co-investorsage1Bold Capital PartnersCornucopian Capital ManagementCRV (Charles River Ventures)GaingelsLifespan Vision Ventures+4 more
__Twitter.png)
Enhanced develops a scientific platform that combines sports performance analysis with human potential optimization.
AI & Machine LearningConsumerDigital HealthHealthtechSports TechWellness & Fitness
Maximilian Martin(Co-Founder & CEO)inChristian Angermayer(Co-Founder & Executive Chairman)Dr Aron D'Souza(Founder)
Co-investorsBig Brain HoldingsDCVC (Data Collective)Decisive PointFlowdeskGSRInitialized Capital+3 more
General Proximity develops proximity-based technologies for drug discovery and development.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Armand Cognetta(Founder)inMatthias PauthnerCorentine Laurin(Principal Scientist, Medicinal Chemistry)Veronica Fulton(Chief of Staff)Benji Dote(EA)Reen Ramos(EA)
Co-investorsY Combinatorage1Felicis VenturesFreemind InvestmentsLifespan Vision VenturesMana Ventures+4 more
HeraSight develops genetic tests for families, including preimplantation embryo screening that uses polygenic risk scores and carrier screening to predict risks for conditions such as Alzheimer's, schizophrenia, cancers, autism, and diabetes.
BiotechDigital HealthHealthtech
Co-investorsDraper AssociatesNZVC
ImmuneBridge is a company working in cell-based cancer immunotherapy, including research on engineered natural killer cells for solid tumor treatment.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSan Francisco, US
Peretz Partensky(Executive Officer, Director)inStuart Alexander Jacobson(Executive Officer, Director)Nina Horowitz(Chief Executive Officer)inRui Tostoes(Chief Technology Officer)inAlicia Jackson(Director)in
BoardDylan Morris(Director)in
Co-investorsGaingelsM VenturesNFXPioneerHealthspan CapitalInsight Partners+2 more
Ladder Bio (formerly ThirdLaw Molecular) develops Spiroligomer molecules, a class of synthetic, modular fused-ring compounds designed for highly selective binding to target proteins, along with computational design tools for targeted drug discovery.
BiotechDeep TechMedical DevicesBlue Bell, US
Christian Schafmeister(Founder)inEric Heil(Chief Executive Officer)in
Co-investorsMedical Excellence CapitalHatch BioFundSmartGateVC
Lucis provides personalized health monitoring and guidance by combining laboratory biomarker testing with educational insights and actionable recommendations.
AI & Machine LearningDigital HealthHealthtechWellness & FitnessParis, FR
Max Berthelot(CEO)inBaptiste Debever(CTO)inJulien Do Vale(M.D., MSc, Chief Medical Officer)inMax Guerois
BoardAntoine Andremont(M.D., PHD, President of the scientific board)Jérémy Bos(MD, MSc, Specialist in public health and clinical epidemiology)
Co-investorsCircle & Co.CloverGeneral CatalystKima VenturesMotier VenturesNorth South Ventures+7 more
.png)
Notion offers a workspace platform for teams to manage projects, documentation, and tasks through customizable views like Gantt charts and Kanban boards.
AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSSan Francisco, US
Ivan Zhao(Founder)inAkshay Kothari(Founder)Simon Last(Founder)in
Co-investorsA.Capital VenturesA*Base10 PartnersCoatue ManagementCraft VenturesDesigner Fund+34 more
.jpeg){kind=logo}
Oisín Biotechnologies develops non-viral genetic therapies built on its Fusogenix Proteo-Lipid Vehicle (PLV) delivery platform, which delivers DNA and RNA payloads to tissues throughout the body and allows repeat dosing.
BiotechHealthtechLongevitySeattle, US
Matthew Scholz(Executive Officer, Director)inEric Garcia(Executive Officer)inStephen Hilbert(Executive Officer)John Lewis(Executive Officer)inGary Hudson(Executive Officer, Director)in
BoardDavid Gobel(Director)
Co-investorsIKJ CapitalMethuselah FundsHealthspan Capital
Renewal Bio is a biotechnology company conducting research related to aging and longevity.
Repair Biotechnologies develops the Cholesterol Degrading Platform, a therapeutic approach for treating conditions caused by localized accumulations of excess cholesterol.
BiotechHealthtechMedical DevicesSyracuse, US
Guilherme Cherman Perdigao de Oliveira(Executive Officer, Director)Reason("CEO's full legal name is ""Reason""")Anthony Matthew Chow(Director)
BoardKelsey Moody(Director)
Co-investorsMethuselah FoundationquadraScope Venture FundThynk Capital
Revel Pharmaceuticals develops enzyme-based therapeutics designed to recognize and reverse molecular damage that accumulates in the body's structural tissue — collagen, elastin, and extracellular matrix — targeting age-related damage that drives disease.
BiotechDeep TechLongevitySan Francisco, US
Aaron Cravens(Co-Founder & CEO)inJennifer Cochran(Director)
Co-investorsGaingels
Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation.
BiotechDeep TechMedical DevicesChicago, US
Ryan Clarke(Co-Founder, Chief Scientific Officer)inNiko Balanis, PhD(Co-Founder, Chief Technology Officer)inBrad Merrill, PhD(Co-Founder, Head of Innovation)Matt MacDougall, MD, PhD(Scientific Cofounder, Immunology Physician, Stanford University)inPatrick Shaddow(Executive Officer, Director)John Craighead, PhD(Chief Executive Officer)
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)DCVC BioDraper AssociatesIllumina VenturesPortal Innovations+1 more
Vincere Biosciences develops small-molecule therapeutics targeting mitochondrial quality control and mitophagy, primarily for neurodegenerative diseases including Parkinson's disease.
AI & Machine LearningBiotechDeep TechLongevity
Co-investorsAlumni VenturesBeiersdorf Innovation FundBeresford VenturesDraper AssociatesFreemind InvestmentsPortal Innovations+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ahead Cloud 141Telos BiotechTotality Biosciences
Portfolio news
latest coverage across their companies
Adaptyv · european-biotechnology.com · Sep 1, 2026
Lucis · lucis.life · May 26, 2026
Frequently asked questions
- How many investments has Long Game made?
- Long Game has 21 tracked investments, including 2 dated in the last 24 months.
- What stage does Long Game invest at?
- Long Game invests at the Pre-Seed, Seed stages.
- What sectors does Long Game focus on?
- Long Game focuses on Biotech, Deep Tech, Healthtech, Longevity.
- Where is Long Game located?
- Long Game is headquartered in London, GB.
- Who does Long Game co-invest with?
- Long Game most often shares deals with Gaingels, age1, Draper Associates, among 76 tracked co-investors.
Similar investors
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
PsyMed Ventures is an early-stage venture firm investing in neuroscience and frontier technologies aimed at improving brain and mental health.
General Inception (GI) partners with technical and scientific founders to co-found and build deep tech, science-based startups, providing people, customers, funding connections, and operational support from idea through seed investment and scaling.
Crista Galli Ventures is a family office founded and run by physician scientists that invests in health and life-science innovation, backing exceptional founders and evidence-driven breakthroughs.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.